Shares pop after an SEC filing reveals that the biopharma has attracted the attention of a major financial institution.
Shares rose in response to news that a large investment management company has purchased a significant ownership position.
Optimism continues to rise for the innovative medical-device maker.
The popular direct-to-consumer bed brand is going public, but investors might want to nap on it.
Shares soar after the clinical-stage biotech releases exciting news.
Shares jump after the company releases upbeat clinical news.
The company announced a lucrative business transaction and provided a sneak peek at fourth-quarter results.
Shares plunge after the company announces preliminary quarterly results that came up short.
Shares are trading on the cheap, but are they too risky to touch?
The company reported upbeat quarterly results and boosted full-year guidance.
Shares more than doubled after the gene therapy company announced that it has accepted a buyout offer. Here are the key details.
Shares jump after the company announces a pair of collaborations and a capital raise. Here are the key details.
Shares jump after the company reports upbeat clinical results. Here are the must-know details.
Aesthetics surgery is a big market, and these three companies are positioned to win from its growth.
Exclusive Interview: Livongo Health CEO on Chronic Illness, the U.S. Healthcare System, and Its Opportunity
CEO Zane Burke talks about his company's business model, consumer experience, international expansion, risks, and more.
Looking for values in today's pricey stock market? Start your search with these five businesses.
The rally continues.
The clinical-stage biotech announced wonderful phase 3 results.
Shares slump after a pair of clinical studies raises new questions about the safety and cost effectiveness of Abiomed's family of heart pumps. Here are the must-know details.
Guardant, Dexcom, and Insulet nailed their quarters and have massive room to grow in the long run, too.